Company Overview and News

 
China Cinda denies providing capital support to troubled food conglomerate Xiwang

2017-03-31 scmp
The companies are in talks but no agreement on financial support has been reached, says assistant president Chen Yanqing

 
China launches pilot offshore bond issuance scheme

2017-02-14 scmp
China Huawei, together with 10 state-owned financial institutions, have been selected to join a pilot programme that grants more flexibility for offshore funding, a statement issued by the National Development and Reform Commission (NDRC) on Tuesday said.

 
China Is About to Get Serious With Bad Debt - Bloomberg

2016-09-04 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

 
China’s debt-to-equity swap plan may struggle to take off

2016-08-31 scmp
The program will face significant challenges including stakeholder interest conflicts and finding new capital sourcing, analysts say

 
What Cinda’s financing model means for the property sector

2016-07-12 scmp
Is this the new normal? State-owned enterprises using their financial muscle to amass land as an asset rather than for its development potential

 
Debt for equity swaps must be done by professional firms, says Huarong chief

2016-03-18 scmp
Move will help avoid ‘moral hazards’ in plan as policymakers are yet to decide way forward

 
SouthGobi Resources Announces Appointment of Non-Executive Director

2016-02-22 marketwired
HONG KONG, CHINA--(Marketwired - Feb. 22, 2016) - SouthGobi Resources Ltd. (TSX:SGQ)(HKSE:1878) ("SouthGobi" or the "Company") today announces appointment of Mr. Huiyi Wang as non-executive director of the Company, effective February 18, 2016. Mr. Wang, 28, is currently an investment associate in China Cinda (HK) Holdings Company Limited ("Cinda HK"),...

 
UPDATE 1-KKR, China Orient team up to invest in property-related bad debt

2016-01-22 reuters
BEIJING/SHANGHAI KKR & Co said it had partnered with one of China's biggest state-owned bad debt managers to take advantage of opportunities in the country's growing market for distressed debt, particularly in the property sector.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...